Baseline Demographics and Clinical Characteristics From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

This work was sponsored by Alkermes, Inc. INTRODUCTION: There are gaps in understanding the role of atypical long-acting injectable (aLAI) antipsychotics in treating schizophrenia in “real-world” settings. OASIS (NCT03919994) was a prospective observational study evaluating outcomes associated with the use of aLAI antipsychotics in routine care. This presentation reviews OASIS study design and patient/location-of-care characteristics. METHODS AND DESIGN: Adults (≥18 years) with schizophrenia who newly initiated 1 of 4 aLAI antipsychotics (aripiprazole lauroxil, aripiprazole monohydrate, paliperidone palmitate, or risperidone) were eligible. Patients were evaluated up to 12 months thereafter according to clinicians’ discretion. RESULTS: Patients with schizophrenia (Nf277) had a mean age of 37.7 (SD=14.9) years. Most patients were male (65.7%), White (47.3%), unemployed (53.1%) or on disability (27.1%), and insured by Medicaid (46.9%) or Medicare (30.3%). Mean time since diagnosis was 11.9 (SD=12.5) years; comorbid anxiety, depression, and substance use disorder were common. Baseline symptom severity was moderate (mean CGI-S: 4.21 [SD=1.06]). Only 34.7% reported antipsychotic use in the 12 months before study enrollment, most commonly with oral antipsychotics. Most patients were treated in community mental health clinics (46.2%) or private practices (45.1%); most initiated treatment as outpatients (63.9%) vs inpatients (11.9%). Travel was a frequent challenge to accessing care. CONCLUSION: Patients initiating aLAI antipsychotics in OASIS had moderate symptoms at baseline and were mostly treated in community/private practice settings as outpatients. Only one-third of patients used an antipsychotic during the 12 months before aLAI initiation in OASIS. Study findings will add “real-world” data facilitating our understanding of the role of aLAI antipsychotic use in schizophrenia.